Protara Therapeutics, Inc. (TARA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US74365U1079
Protara Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -64.55 m USD |
| EBIT | -63.82 m USD |
| Net income | -57.44 m USD |
| Diluted EPS – continuing operations | -1.34 USD |
Full history since 2009, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Protara Therapeutics, Inc.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
More stocks
- Srivichaivejvivat Public Company Limited (VIH.BK)
- Daol Investment & Securities (030210.KS)
- Tway Air Co Ltd (091810.KS)
- Yoda Pharmaceuticals Inc. (7829.TWO)
- JD Bancshares Inc (JDVB)
- Carlo Gavazzi Holding AG (GAV.SW)
- Cystech Electronics Corp (6651.TWO)
- Aiptek International Inc (6225.TW)
- ESTec Corporation (069510.KQ)
- Goliath Resources Ltd (GOT.V)
- Tachan Securities Co Ltd (6020.TWO)
- SAB Finance as (SABFG.PR)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.